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Chemo-manipulation of tumor 
blood vessels by a metal-based 
anticancer complex enhances 
antitumor therapy
Tina Riedel1, Sabrina Cavin2, Hubert van den Bergh1, Thorsten Krueger2, Lucas Liaudet3, 
Hans-Beat Ris2, Paul J. Dyson1 & Jean Y. Perentes2
Human pleural mesothelioma is an incurable and chemoresistant cancer. Using a nude mouse xenograft 
model of human pleural mesothelioma, we show that RAPTA-T, a compound undergoing preclinical 
evaluation, enhances tumor vascular function by decreasing blood vessel tortuosity and dilation, 
while increasing the coverage of endothelial cells by pericytes and vessel perfusion within tumors. 
This in turn significantly reduces the interstitial fluid pressure and increases oxygenation in the tumor. 
Consequently, RAPTA-T pre-treatment followed by the application of cisplatin or liposomal cisplatin 
(Lipoplatin) leads to increased levels of the cytotoxin in the tumor and enhanced mesothelioma 
growth inhibition. We demonstrate that the vascular changes induced by RAPTA-T are related, in part, 
to the inhibition of poly-(ADP-ribose) polymerase 1 (PARP-1) which is associated to tumor vascular 
stabilization. These findings suggest novel therapeutic implications for RAPTA-T to create conditions 
for superior drug uptake and efficacy of approved cytotoxic anti-cancer drugs in malignant pleural 
mesothelioma and potentially other chemoresistant tumors.
Malignant pleural mesothelioma is an aggressive cancer for which curative treatments are not available at present. 
The disease is caused, in general, by the inhalation of asbestos fibers and develops in the pleura or peritoneum, 
composed of a single layer of mesothelial cells resting on a thin membrane of connective tissue, which surround 
the lungs and the bowel. Early-stage pleural mesothelioma can be surgically removed in the context of multi-
modal therapy including chemo- and/or radiation therapy, but has very high recurrence rates1,2. Many patients 
are diagnosed at an advanced stage of the disease, at which point most therapies are ineffective and surgery is only 
performed with a palliative intent2. The median survival time for patients is ≤15 months depending on the stage 
of disease progression at the time of diagnosis. Since 2003, the standard chemotherapy regimen for induction 
and palliative treatment has been the combination of cisplatin with pemetrexed. While survival was proven to 
be enhanced, the median time to progression was only of 5.7 months3,4. Despite many attempts, until now, no 
regimen has further improved survival.
There is increasing evidence that efficacy of chemotherapy is often limited by insufficient uptake and distribu-
tion in tumors. Anticancer drugs must reach target tumor cells through blood vessels and then penetrate through 
the tumor tissue, a mechanism that relies on diffusion and convection. One barrier for efficient drug delivery in 
solid tumors is the morphologically and functionally abnormal tumor vasculature characterized by chaotic angio-
genesis and highly permeable blood vessels that lead to elevated tumor interstitial fluid pressure5. High interstitial 
fluid pressure is thought to impede convection and, for this reason, to cause unfavorable drug transport condi-
tions within tumors. The latter is, in turn, believed to be responsible for the poor response of tumors to chemo-
therapy and their recurrence6. Ways to improve tumor vasculature and drug transport have since been described. 
Jain et al. first demonstrated that anti-angiogenic therapy at low doses could normalize the vasculature of solid 
tumors leaving behind a more mature and functional vessel network by selectively pruning immature blood ves-
sels7,8. This process enhances tumor oxygenation and drug transport, thus improving the effect of radiation- and 
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chemotherapy7,8. Vascular normalization with VEGF and VEGFR inhibitors has been demonstrated in several 
preclinical cancer models7,8. Recently, the normalization concept was also confirmed in patients with colorectal 
and brain tumors9,10. However, the application of anti-angiogenic therapies to achieve vascular normalization 
requires a fine-tuned dose control; a too small dose has no effect whereas a too high dose prunes away all vessels. 
In addition, anti-angiogenic treatments are notorious for their side effects on wound healing, blood pressure 
modulations and kidney toxicity10. Thus, the clinical translation of vascular normalization has remained difficult 
in patients. Other approaches are currently being studied to optimize vascular normalization while avoiding side 
effects, including more specific vascular modulating agents such as tyrosine kinase inhibitors11, low dose photo-
dynamic therapy approaches12,13 and others14.
Recently, a new class of promising organometallic anticancer agents (termed RAPTA, Fig. 1A) has been devel-
oped which exhibit a broad spectrum of activity including effects on resistance and sensitizing phenomena of 
cancer cells, but with surprisingly low general cytotoxicity. In preclinical cancer models, RAPTA compounds 
inhibit primary tumor growth and the development of metastases15–17. In addition to their anticancer properties 
these organometallics display anti-angiogenic activity in vivo, although the effect at even high concentrations was 
relatively mild in comparison to other anti-angiogenic compounds18.
Based on the moderate anti-angiogenic activity and low in vitro cytotoxicity on cancer and endothelial 
cells, we hypothesized that these drug properties would be desirable and could be explored to favor vascular 
Figure 1. Real time assessment of MSTO-211H tumor and vascular changes following RAPTA-T treatment. 
(A) Chemical structure of RAPTA-T (Ru(η6-toluene)(PTA)Cl2). (B) Intravital microscopy images at days 0 and 
8 show the progressive vascular changes upon daily RAPTA-T (50, 75, 100 mg kg−1) treatment. White arrows 
point to the vessels that were traced during RAPTA-T treatment (50 mg kg−1) over 8 days in (C). (C) Regions 
with the same vessels (a–d) at day 0 and day 8 in (A) are magnified 20× . Vessels within control tumors at day 
0 and at day 8 were chaotic and dilated with abrupt changes in vessel diameter and direction. Vessels in treated 
tumors day 0 appeared similar to control tumors on day 0 but had a less dilated and more “normal” structural 
phenotype at day 8.
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normalization without risking too high anti-angiogenic activity and excessive vessel pruning. With this objective, 
we assessed the impact of RAPTA-T [Ru(η6-toluene)(PTA)Cl2] treatment on the tumor vascular morphology 
and function in a murine pleural mesothelioma model by real time imaging. We show that RAPTA-T, at a low 
dose, normalizes tumor blood vessels and increases oxygenation through improved vascular function. By com-
bining RAPTA-T with cisplatin, one of the first-line chemotherapeutic agents for mesothelioma, we demonstrate 
improved treatment outcome through higher chemotherapeutic drug uptake into the tumor. Finally, we demon-
strate that RAPTA-T can inhibit Poly(ADP-Ribose) Polymerase type 1 (PARP-1), a nuclear protein involved in 
DNA damage repair and angiogenesis. We show that PARP-1 inhibition is associated with a drop in vascular 
endothelial growth factor secretion in vitro and promotes vascular stabilization in vivo. These results suggest a 
chemotherapeutic combination therapy with RAPTA-T as a novel option in resectable (as neoadjuvant therapy) 
and advanced (as palliative therapy) mesothelioma or for the management of other solid tumor cancer types.
Results
RAPTA-T inhibits tumor Poly(ADP-Ribose) Polymerase type 1 in vitro which decreases tumor 
derived vascular endothelial growth factor (VEGF). As a metal-based compound, RAPTA-T has the 
capacity to dislodge zinc ions from zinc finger proteins and change their conformation and function19. We first 
determined the impact of RAPTA-T on PARP-1 in an in vitro colorimetric assay. We found that PARP-1 activity 
was inhibited by RAPTA with an IC50 of 400 μM (Fig S1A). PARP-1 is activated in response to DNA damage 
induced by various genotoxic agents such as the oxidant H2O2. In turn activated PARP-1 induces PARylation 
of multiple proteins and promotes cell necrosis through ATP depletion. To explore whether RAPTA-T could 
interfere with such processes, we cultured MSTO211H cells in the presence of H2O2 (250 µM), with or without 
pretreatment with RAPTA-T (400 μM), or 3AB (a prototypical PARP-1 inhibitor, 150 µM). The H2O2 cytotoxicity 
was significantly and comparably reduced by 3-AB and RAPTA-T (Fig S1B). Furthermore, the cytoprotective 
effects of 3-AB and RAPTA-T were associated with a trend to a decreased accumulation of PAR polymers in 
cells exposed to H2O2 (Fig S1C). It is also noteworthy that PARP-1 has been shown to be involved in the syn-
thesis of vascular endothelial growth factor (VEGF)20,21. We therefore determined the impact of RAPTA-T on 
VEGF released by MSTO211H cells in culture, and we found that RAPTA-T (400 μM) caused a two-fold drop in 
VEGF-A levels (Fig S1D). Taken together, these results support the notion that RAPTA-T behaves as an inhibitor 
of PARP-1 activity.
RAPTA-T alters the tumor vascular morphology in vivo. RAPTA-T has been shown to have no cyto-
toxic effect on vascular endothelial cells18. Using a cell viability assay, we excluded a direct cytotoxic effect of 
increasing doses of RAPTA-T on cancer cells (Fig S2). We then investigated the effect of RAPTA-T on mesothe-
lioma xenografts in real time by assessing the vascular changes of MSTO-211H tumors grown in dorsal skin-
fold chambers using fluorescence intravital microscopy. The dorsal skinfold chamber is a sophisticated window 
model that allows detailed observation of the effects of a drug on tumor blood vessels over multiple days in a 
non-invasive manner. Functional blood vessels are visualized by injecting a high-molecular weight fluorescent 
molecule (FITC-dextran 2,000 kDa) intravenously prior to imaging. Tumors were treated by daily RAPTA-T 
doses (50, 75 and 100 mg kg−1) for a maximal period of 18 days. None of the RAPTA-T concentrations caused 
tumor shrinkage (Fig. 1B). Progressive tumor vascular changes with increasing doses were observed. Low dose 
RAPTA-T (50 mg kg−1) decreased tumor vascular dilation and tortuosity by day 8 compared to controls (Fig. 1C). 
These characteristics persisted until day 11, but shifted towards vessel regression by day 18 (Fig S3). Higher 
RAPTA-T doses (75 and 100 mg kg−1) caused similar changes but also caused vascular pruning effects by day 8 
(Fig. 1B, Fig S3). In contrast, the vasculature of healthy tissue remained unchanged during the course of treat-
ment at all concentrations. Interestingly, while low dose RAPTA-T was tolerated by animals, higher doses caused 
weight loss and spontaneous deaths over the course of treatment. Based on the observed vascular morphology 
changes and toxicity upon RAPTA-T treatment, we estimated an appropriate treatment window for RAPTA-T at 
a tolerated daily dose of 50 mg kg−1 for a minimum of 8 days and a maximum of 11 days.
Next, the effect of daily RAPTA-T (50 mg kg−1) treatment over 8 days on the vascular density of tumors grown 
in dorsal skinfold chambers was quantified. The density of perfused vessels increased significantly in RAPTA-T 
treated tumors over 8 days (DeBacker’s score index 13.7 ± 3.3 at day 0 and 17.1 ± 3.5 at day 8, P = 0.025, 2-way 
ANOVA, N = 3), whereas in control tumors the perfused vessel density did not change over time (DeBacker’s 
score 10.8 ± 2.6 at day 0 and 10.2 ± 4.1 at day 8, P = 0.629, 2-way ANOVA, N = 4) (Fig. 2A). To assess the effect of 
RAPTA-T on the vessels throughout the depth of tumors, we quantified vessel density of tumor sections stained 
for CD31. Tumors were treated with daily doses of RAPTA-T (50 mg kg−1) over a period of 10 days. Tumor vessel 
diameter at day 11 was also assessed on these sections. There was no significant change in vessel density following 
RAPTA-T treatment compared to controls on day 11 (260 ± 109 vessels/mm2 vs 318 ± 226/mm2, respectively, 
N = 4–5 mice per group, P = 0.56) (Fig. 2B,C). Interestingly, tumor vessel diameter was significantly decreased in 
RAPTA-T tumors compared to controls (18.3 ± 16.4 μm vs 14.0 ± 7.7 μm, respectively, N = 4–5 mice per group, 
Fig. 2D), with a shift from 20 μm and larger diameter vessels to 5–15 μm diameter vessels (N = 120–140 vessels 
per group, Fig. 2E).
RAPTA-T reduces interstitial fluid pressure (IFP), improves vascular function and transport in 
tumors and enhances cisplatin uptake. Abnormal blood vessel function contributes to elevated IFP in 
tumors, which in turn adds to a decreased transcapillary transport and impairs drug delivery throughout tum-
ors6. We evaluated how daily RAPTA-T (50 mg kg−1) treatment affected tumor interstitial fluid pressure (IFP) in 
MSTO-211H tumors over a period of 8 days. Between days 0 and 4, there were no significant changes in IFP of the 
tumor and surrounding normal tissue between the control and RAPTA-T treated tumors. From day 5 to day 8, a 
significant drop in tumor IFP was observed in the RAPTA-T treated group, but not in controls (∆mmHg 0.2 ± 3.5 
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on day 4 and −5.6 ± 2.07 on day 8 for RAPTA-T treated group (P = 0.003) vs ∆mmHg 0.3 ± 3.6 on day 4 and 
3.0 ± 3.2 on day 8 for control group (P = 0.19). At day 8, RAPTA-T treated tumors had a significantly lower IFP 
compared to controls (5.7 ± 3.5 vs 13.2 ± 1.1 mmHg, N = 6–7 mice per group, P < 0.0001 2-way ANOVA, Fig. 3).
To determine whether RAPTA-T modulated the vascular wall structure, we assessed tumor vascular peri-
cyte coverage by double-immunostaining of the endothelial cell marker CD31 and the pericyte marker α-SMA. 
On day 11, we found more α-SMA-positive pericytes that were partially detached from the vessels in control 
tumors compared to RAPTA-T treated tumors, where tighter contacts between pericytes and endothelial cells 
were observed (Fig. 4A). Pericyte coverage was significantly enhanced in RAPTA-T (50 mg kg−1) treated tumors 
compared to controls (34.6 ± 19.2 vs 21.5 ± 16.3% α-SMA-positive vessels, respectively, Fig. 4A,C, P < 0.001, 
unpaired t-test). Also, the endothelial cell lining was more homogeneous in RAPTA-T treated tumors compared 
Figure 2. Change of vessel density and diameter following 8 and 10 days of 50 mg kg−1 RAPTA-T treatment. 
(A) Quantitiation of tumor vessel density in dorsal skinfold chambers by the DeBacker method after 8 
days of treatment. Vessel density slightly increases from day 0 to day 8 in RAPTA-T treated tumors (N = 3, 
DeBacker’s score 13.7 ± 3.3 at day 0 and 17.1 ± 3.5 at day 8, P = 0.025, 2-way ANOVA), but not in controls 
(N = 4, DeBacker’s score 10.8 ± 2.6 at day 0 and 10.2 ± 4.1 at day 8, P = 0.63, 2-way ANOVA). Data represent 
mean ± SD. (B) Representative brightfield tumor sections stained for CD31 (magnification x40) after 10 days of 
treatment. (C) Microvessel density (MVD) was counted as number of vessels per mm2 in controls (N = 4, a and 
c) and RAPTA-T treated tumors (N = 5, b and d). The mean vascular density was 318 ± 226 for control tumors 
and 260 ± 109 vessels/mm2 for RAPTA-T treated tumors, respectively, after 10 days of treatment. Data represent 
mean ± SD. (P = 0.56, unpaired t-test, Mann-Whitney). (D) Mean vessel diameter was significantly decreased in 
RAPTA-T treated tumors compared to control tumors (18.3 ± 16.4 vs 14.0 ± 7.7, respectively, N = 4–5 mice per 
group). (E) Percentage frequency distribution of vessel diameters shows a shift from 20 μm and larger diameter 
vessels in control tumors to 5–15 μm diameter vessels in RAPTA-T treated tumors (N = 120–140 vessels per 
group).
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to controls. In addition, there were significantly less α-SMA-positive stained cells away from the vessel perim-
eter in RAPTA-T treated tumors compared to controls (***P < 0.001 unpaired t-test with Welch’s correction, 
Fig. 4B,D).
Based on our in vitro findings where RAPTA-T could lead to PARP-1 inhibition, we determined how tumor 
derived PAR levels correlated with vascular pericyte coverage by immunohistochemistry in vivo. We found that 
enhanced pericyte covage in the RAPTA-T treated tumors correlated with a drop in tumor derived PAR (linear 
correlation), while this was not the case in the control tumors (Fig. 4E,F).
Given the properties of RAPTA-T to correct morphological and functional vessel abnormalities shown by 
improved vascular pericyte coverage and reduced IFP, blood flow in tumor vessels would be expected to be 
improved after treatment, which in turn would improve tumor oxygenation and hence reduce hypoxia. According 
to this hypothesis, we found that daily RAPTA-T treatment over 10 consecutive days significantly decreased 
tumor hypoxia by day 11 compared to controls (Fig. 5A–C). Also, the spatial distribution of the pimonidazole 
stain suggested that hypoxia was mostly decreased in the central region of tumors with RAPTA-T treatment. In 
parallel, we also determined the overall extracellular matrix changes in RAPTA-T treated and control tumors. 
RAPTA-T therapy did not cause changes in the Collagen I and hyaluronic acid content of mesothelioma tumors 
compared to controls in heterotopic and orthotopic tumors (Fig. 5D and Fig S4A).
We then assessed how vascular modulation by RAPTA-T affected the transport of a macromolecular fluo-
rescent dye (FITC-dextran 2,000 kDa). FITC-dextran was more homogeneously distributed and accumulated 
significantly more throughout tumors following 8 consecutive days of RAPTA-T treatment compared to controls 
(Fig. 6A,B). Again, the central core of the tumors showed most of the enhanced tracer distribution in RAPTA-T 
treated tumors, whereas in control tumors fluorescence was mainly confined to the tumor periphery (Fig. 6A). 
These results are supported by the quantitative analysis of vessel density on intravital microscopy images using the 
DeBacker method which show a higher density of perfused vessels at day 8 in RAPTA-T treated tumors compared 
to controls (P = 0.001, unpaired t-test, Fig. 2A).
To determine if the enhanced vascular transport of the fluorescent tracer translated into better drug uptake, 
we combined 10 days of RAPTA-T treatment with a single cisplatin dose on day 11 in MSTO-211H mesothe-
lioma xenografts and quantified the cisplatin concentration in tumor tissues by inductively coupled plasma 
mass-spectrometry at day 21. RAPTA-T pre-treatment significantly enhanced the platinum concentrations in 
tumors (0.16 ± 0.05 ng Pt/mg tumor tissue) compared to controls (0.05 ± 0.03 ng Pt/mg tumor tissue, P = 0.005). 
The quantities of residual ruthenium were measured 11 days after pre-treatment and were comparable between 
the RAPTA-T (2.06 ± 0.42 ng/mg tumor tissue) and RAPTA-T + cisplatin combination group (246 ± 0.31 ng/mg 
tumor tissue, Fig. 6C). Interestingly, while RAPTA-T treatment alone had no significant effect on tumor growth 
by day 21 compared to control, there was a significant decrease in tumor growth of the RAPTA-T combination 
with cisplatin compared to cisplatin alone (333 ± 88 vs 164 ± 65 mm3 at day 21, respectively, p < 0.005, Fig S5). 
Taken together, these findings suggest that improvements in vascular function through RAPTA-T pre-treatment 
enhance the molecular transport of cisplatin across the tumor vasculature to reach target cancer cells.
RAPTA-T pre-treatment improves efficacy of systemically administered lipoplatin in an ortho-
topic mesothelioma tumor model. We next evaluated how the alterations in tumor vessel structure and 
function through pre-treatment with RAPTA-T affected the impact of lipoplatin chemotherapy on orthotopic 
pleural mesothelioma in mice. We initially confirmed that vascular stabilization under the form of enhanced 
pericyte coverage occurred in MSTO211H tumors (Fig S4B,C). Nude mice with established orthotopic H-meso-1 
pleural mesothelioma were given daily doses of RAPTA-T (50 mg kg−1) or 0.9% NaCl (aq.) as the control over 
a period of 8 days (21 days after tumor cell inoculation). Subsequently, these mice received a single i.p. dose of 
lipoplatin (18 mg kg−1, which corresponds to one third of the LD50 concentration for mice (35) 24 h after the 
last RAPTA-T injection (on day 9), and tumor growth was followed by bioluminescence imaging (until day 29). 
RAPTA-T treatment had no effect on tumor growth compared to controls over the 8 day course of pre-treatment. 
Figure 3. RAPTA-T 50 mg kg−1 lowers interstitial fluid pressure in MSTO-211H tumors. IFP measurements 
were performed using the wick-in-needle technique. 50 mg kg−1 RAPTA-T or 0.9% NaCl (aq.) as control 
were given daily i.p. over 8 days. The IFP value was normalized by the value at day 0. Data are represented as 
mean ± SD. ****P < 0.0001 (2-way ANOVA).
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Figure 4. RAPTA-T treatment improves vascular pericyte coverage of tumor vessels. (A) Pericyte coverage 
was determined in MSTO-211H tumors treated with vehicle (left panels) or daily 50 mg kg−1 RAPTA-T (right 
panels) for 10 days. Immunohistochemical double stainings of CD31 and α-SMA show that in control tumors 
α-SMA positive pericytes were partially detached from the vessels (red). Arrows are pointing at loosely attached 
pericytes. In RAPTA-T treated tumors tighter contacts between pericytes and endothelial cells were observed. 
(B) Double staining of CD31 (red) and α-SMA (green) shows significantly more pericyte-covered tumor vessels 
in RAPTA-T treated (right panel) than control MSTO-211H tumors (left panel), quantified in (C). ***P < 0.001 
(unpaired t-test with Welch’s correction) (D) Quantification of α-SMA positive cells, which are not associated 
to endothelial cells, representing cancer-associated fibroblasts. Mean ± SEM, ***P < 0.001 (unpaired t-test with 
Welch’s correction). Fluorescent images were captured at 20x magnification. (E) Triple immunostaining for 
PAR (green), CD31 (white) and alpha-SMA (red) in heterotopic MSTO211H tumors. (F) The graph represents 
the quantification of PAR+ particles in the surrounding of tumor vessels as a function of the vascular pericyte 
coverage (N = 5–4/group, 18–19 fields/group). In RAPTA-T treated tumors, an inverted linear correlation 
between PAR expression and pericyte coverage enhancement was observed.
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While all mice developed tumor regression within 5 days following lipoplatin administration, RAPTA-T com-
bined with lipoplatin caused a significantly higher growth delay compared to lipoplatin alone (growth delay of 
11 ± 1 days with RAPTA-T pre-treatment compared to 6 ± 2 days with lipoplatin alone, P < 0.0001, Fig. 7). Also, 
the rate of tumor re-growth was very similar in both groups. Tumor growth curves of individual mice are shown 
in Fig. S6.
Discussion
Mesothelioma is a chemoresistant cancer for which new treatment regimens and new putative drugs are urgently 
needed. Improved response to chemotherapy and to radiation therapy is mandatory for the management of 
early and more advanced mesotheliomas in the context of a multimodal therapy with curative intent or in the 
context of palliative therapy. In this study we have examined the possible use of the small-molecule organo-
metallic compound RAPTA-T as a tumor vascular modulation agent in pleural mesothelioma and describe a 
possible mechanism of action through PARP-1 inhibition. We show the functional changes that occur result 
from the “remodeling” of the tumor vasculature with RAPTA-T in relevant heterotopic and orthotopic models. 
Figure 5. RAPTA-T treatment reduces tumor hypoxia. Immunohistochemical detection of tumor hypoxia 
with the exogenous 2-nitroimidazole hypoxia marker pimonidazole hydrochloride after daily RAPTA-T 
(50 mg kg−1) treatment for 10 days. Tumor sections of (A) control tumors and (B) treated tumors at day 11 were 
compared, and quantified in (C). After RAPTA-T treatment, tumor hypoxia was reduced significantly (N = 3 
mice per group, P = 0.037, unpaired t-test). Data are represented as mean ± SD. (D) Collagen I and Hyaluronic 
acid content in MSTO211H tumors treated by RAPTA-T or control. The quantification does not reveal any 
significant difference in heterotopic tumors.
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The abnormal structure and function of the tumor vasculature, comprising leaky and compressed vessels, leads 
to a microenvironment within solid tumors that is characterized by elevated IFP, inefficient tumor perfusion and 
focal hypoxia7,8. These factors impede the delivery of molecular therapeutics within tumors, induce peri-tumoral 
edema, impair tumor response, promote recurrence and can contribute to metastatic spread5. Thus, repairing an 
abnormal and heterogeneous microenvironment – and improving oxygen distribution in particular – can signif-
icantly improve tumor treatment including subsequent chemo- and radiation therapy and potentially immuno-
therapy. To the best of our knowledge, this is the first study to show that vessel modulation with an organometallic 
drug has functional consequences with regards to the intratumoral delivery and antitumor activity of subse-
quently administered chemotherapeutic drugs cisplatin and Lipoplatin.
A hallmark of solid tumors is their elevated IFP, which results from their highly permeable angiogenic vessel 
network as well as the absence of functional lymphatics6. These vascular characteristics represent barriers for 
therapy as they affect distribution and tumor oxygenation. Unpublished work from mesothelioma patients as 
well as from orthotopic models in rats has shown that mesothelioma is characterized by elevated interstitial fluid 
pressure (in the range of 3 to 4 mmHg)12. Continuous low dose administration over 10 days of RAPTA-T to mice 
bearing MSTO-211H xenograft tumors results in the disappearance of tortuous and dilated tumor vessels leading 
to a more homogeneous vascular network (Fig. 1) with smaller vessels of more uniform diameter size (Fig. 2D,E) 
Figure 6. RAPTA-T pre-treatment improves vascular transport in tumors. (A) The effect of RAPTA-T on 
tumor perfusion in established MSTO-211H mesothelioma tumors (black dotted lines) in dorsal skinfold 
chambers was determined by measuring the distribution of a high molecular weight FITC-dextran (2,000 kDa) 
tracer (white dotted lines). (B) Within RAPTA-T treated tumors there was significantly more FITC-dextran 
extravasation with a more homogenous fluorescence signal throughout the tumor mass at day 8 compared 
with controls. (C) MSTO-211H tumors of mice (N = 4 per group) treated with RAPTA-T alone, cisplatin alone 
or the RAPTA/cisplatin combination were each analysed by ICP-MS for their Ruthenium (Ru) and Platinum 
(Pl) metal content. Mice treated with RAPTA-T or cisplatin alone had sole detection of Ru and Pl respectively 
(columns 1–2). Mice pre-treated with 50 mg kg−1 RAPTA-T showed an increased uptake of cisplatin into tumor 
tissue compared to mice treated with cisplatin alone but no difference in the Ru content (**P < 0.005, unpaired 
t-test). Data are represented as mean ± SD.
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and better perfusion (Fig. 6A). In contrast to a number of other studies7,8,22 concerned with anti-angiogenic ther-
apy using VEGFR2 inhibitors or tyrosine kinase inhibitors, we found that reduced IFP (Fig. 3) is not positively 
correlated with a decrease in overall vessel density (Fig. 2A–C). These other studies demonstrated normalization 
of the tumor vasculature with a decreasing fraction of immature small tumor vessels that lack coverage by smooth 
muscle cells and pericytes. Consequently, a drift to higher mean tumor vessel diameters and reduced perfused 
vessel density was found. RAPTA-T, however, at the applied dose and window, was not found to prune vessels 
(Fig. 1), which is in accordance with the tumor growth rate within this apparent normalization window not being 
significantly inhibited (Fig. 1B and Fig S6B). Instead, RAPTA-T therapy was associated with vessel maturation 
leading to better transport properties (better tracer/drug distribution, better oxygenation) and lower permeability 
(decrease in tumor IFP).
On a cellular level, immunohistological analyses show that RAPTA-T treatment leads to an increase in 
the amount of microvessels covered by α-SMA+ pericytes (Fig. 4B,C). In tumors, an abnormal phenotype of 
α-SMA-expressing pericytes has been described23,24, in which pericytes are often partially detached from 
endothelial cells with abnormal shapes and long processes away from the vessel wall. These abnormalities have 
been previously described as characteristics of malfunctioning leaky vessels with wide junctions, which lead to 
increased IFP, and are closely linked to poor tumor perfusion and hypoxia. Our findings suggest that vascular 
function can be improved with RAPTA-T through the activation of pericytes and enhancement of their coverage 
of endothelial cells. Also, based on our in vitro and in vivo findings, RAPTA-T inhibits PARP-1, which has been 
shown to be important in the process of angiogenesis, possibly through modulation of MAP kinase-dependent 
regulation of angiogenic factor balance20,25. RAPTA-T-dependent PARP-1 inhibition was indeed associated with 
Figure 7. RAPTA-T pre-treatment enhances growth delay of subsequently applied drug lipoplatin in an 
orthotopic Hmeso-1 human mesothelioma xenograft model. Representative bioluminescence images following 
tumor growth of (A) RAPTA-T pre-treated and (B) control mouse. RAPTA-T or vehicle was given in eight 
subsequent injections (50 mg kg−1 body weight RAPTA-T or saline, i.p. every 24 hours from day 1 to 8) followed 
by a single injection of lipoplatin (18 mg kg−1) administered i.p. on day 9 to both pre-treated and control groups. 
The total photon flux released by luciferase-expressing Hmeso-1-tumor cells was measured after i.p. injection 
of D-luciferin (150 mg kg−1) in dorsal and ventral positions (upper and lower panel of images, respectively). (C) 
Lipoplatin leads to enhanced growth inhibition and delays tumor re-growth by 5 ± 2 days when administered 
after RAPTA-T pre-treatment (growth delay 11 ± 1 days with RAPTA-T pre-treatment compared to 6 ± 2 
days with lipoplatin alone, P = 0.0049, unpaired t-test). Data represent the average of photon flux/s (log scale) 
measured from dorsal and ventral positions of mice (N = 4 per group) and are normalized to the photon flux 
before lipoplatin administration (day −1) and given as mean ± SD.
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a drop in tumor cell-derived VEGF (Fig S1D). In addition, tumor cell PAR expression was significantly decreased 
in the areas of enhanced pericyte coverage of MSTO211H tumors grown in mice. Combined, this suggests that 
PARP-1 inhibition is mechanistically involved in the RAPTA-T-induced changes on the tumor vasculature. These 
findings are consistent with previous studied indicating that RAPTA-T can inhibit PARP activity19.
Based on our findings, PARP-1 was inhibited by RAPTA-T resulting in a two-fold drop in VEGF-A secretion 
by MSTO211H tumor cells. By tumor immunostaining analysis, we found a linear correlation between tumor 
derived PARP-1 expression decrease and enhanced pericyte vascular coverage in RAPTA-T treated tumors. It is 
well established that anti-VEGF therapy is associated to enhanced vascular pericyte coverage in tumors which 
decreases IFP and improves vascular transport7,8. Together, this suggests that PARP-1 inhibition by RAPTA-T 
participates in vascular stabilization through a drop in VEGF-A levels.
In addition, an effect of RAPTA-T on cancer associated-fibroblasts (CAFs), which are also known to be 
α-SMA immunoreactive, cannot be excluded given the lower number of α-SMA+ cells in the tumor interstitium 
upon treatment (Fig. 4B,D). CAFs are among the major cell populations within stromal compartments, known 
for their source of pro-angiogenic growth factors, extracellular matrix (ECM) remodeling proteins and produc-
tion of ECM components, which mediate cancer growth and metastasis and impede efficient chemotherapeutic 
drug delivery26,27. Interestingly, ECM changes induced by a decrease in overall CAFs in tumors was not observed 
with collagen type I and hyaluronic acid (HA) staining, that remained comparable between RAPTA-T treated 
and control tumors.
Tumor vascular functionality is a contributing factor of the effectiveness of cytotoxic chemotherapy. Similar 
to low dose antiangiogenic therapy that has been shown to provide a short-term “normalization window” where 
vascular functions are improved by reducing vascular leakage and increased tumor oxygenation, 8–10 days of 
RAPTA-T treatment offers the benefit of enhanced antitumor effect when administered in combination with 
cisplatin during that time window. The combination of RAPTA-T pre-treatment with cisplatin, the standard treat-
ment for pleural mesothelioma in the clinic, leads to a better antitumor effect in a heterotopic mouse model than 
either therapy alone (Fig S6B,C). Increased levels of cisplatin were detected inside the tissue of tumors pre-treated 
with RAPTA-T compared to tumors that received no pre-treatment (Fig. 6C), thus demonstrating increased drug 
uptake into tumors with improved vascular function and supporting the hypothesis that changes to the vascula-
ture induced by RAPTA-T leads to a better distribution of the cytotoxic drug. We further confirmed the beneficial 
vascular transport conditions created by RAPTA-T in an orthotopic mesothelioma model by pre-treating with 
RAPTA-T followed by lipoplatin, and demonstrated improved tumor regression for a longer period of time in 
tumors pre-treated with RAPTA-T compared to tumors that did not receive the pre-treatment (Fig. 7).
The limited efficacy of cisplatin for mesothelioma is potentially due to limited amounts of the drug that enters 
the tumor. The typical high interstitial pressure in mesothelioma can be a major barrier to drug delivery and 
distribution, especially for macromolecular drugs, which rely on convection rather than diffusion for their tumor 
penetration. RAPTA-T caused a significant decrease in tumor IFP in our study which was associated to enhanced 
vascular pericyte coverage (vessel stabilization). The latter would result in decreased permeability, enhanced con-
vection and drug distribution. Alternative effects of RAPTA-T could be related to an improved overall vascular 
perfusion that is suggested by the increased vascular density assessed by intravital microscopy and the decreased 
hypoxemic tumor regions (based on the pimonidazol immunostainings). Cisplatin and lipoplatin differ signif-
icantly in size, however the potential binding of cisplatin to the plasma protein albumin suggests a convective 
transport for the small molecule drug28. We observed enhanced distribution of both with RAPTA-T treatment. 
Vessel stabilization combined with enhanced perfusion (and oxygenation) are likely the contributing factors that 
helped to enhance drug distribution for both cisplatin and lipoplatin. Some studies have suggested that extracel-
lular matrix content could affect regional blood perfusion through shear stress27. However, although tumor asso-
ciated fibroblasts (alpha-SMA positive cells not associated to vessels) increased with RAPTA-T, our extracellular 
matrix analysis failed to show a difference in RAPTA-T treated tumors compared to controls regarding collagen 
and hyaluronic acid content. The increased uptake of the chemotherapeutic drug through pre-treatment with 
RAPTA-T significantly improves the treatment outcome of mesothelioma and potentially other cancer types. In 
addition, the enhanced oxygenation within tumors is also a predictor of better response of tumors to radiation 
therapy, as previously shown with anti-angiogenic therapy, and suggestive of a better response of these tumors to 
radiation therapy.
Methods
Compounds. RAPTA-T was prepared as previously described17.Cisplatin was obtained from TCI 
(Zwjndrecht, Belgium) and liposomal cisplatin (Lipoplatin) was purchased from Regulon (Athens, Greece). 
FITC-dextran (2,000 kDa) was purchased from Sigma-Aldrich (Buchs, Switzerland).
Tumor cell lines and cell culture. The human mesothelioma MTSO-211H cell line was obtained from the 
American Type Culture Collection (American Type Culture Collection LGC Standards GmbH, Wesel, Germany) 
and H-Meso-1 from CLS Cell Lines Service GmbH (Eppelheim, Germany). Both were cultured in RPMI 1640 
medium supplemented with HEPES (Thermo Fisher Scientific, Reinach, Switzerland) and 10% fetal bovine serum 
(PAN Biotech, Eidenbach, Germany). The H-Meso-1 cell line was transfected with a luciferase lentiviral construct 
(pGL3) as described previously (H-Meso-1-lucP,29. The H-Meso-1-lucP cell line was routinely passaged with 
2 µgmL−1 puromycin as selection antibiotic in the cell culture medium to ensure the stable expression of luciferase 
in this cell line. Cells were grown in a humidified atmosphere with 5% CO2 at 37 °C and regularly checked to be 
free of Mycoplasma contamination.
Animals. All animal experiments were approved by the Institutional Animal Care and Use Committee of 
the University of Lausanne (Authorization VD2923). All procedures were carried out in accordance with the 
www.nature.com/scientificreports/
1 1SCientifiC REPORTS |  (2018) 8:10263  | DOI:10.1038/s41598-018-28589-2
approved guidelines. Six-week old female Swiss nude mice were purchased from Charles River (Lyon, France). 
All animals were kept in a specific pathogen free environment, which included filtered air, sterilized food, water, 
bedding and cages until their visualization. All surgeries and imaging of the dorsal skinfold chamber were per-
formed under ketamine/xylazine anesthesia to avoid any hypotension.
Dorsal Skinfold Chamber Model. MSTO-211H human mesothelioma cells (5 × 105 cells) were inoculated 
in serum-free RPMI 1640 medium in the subcutaneous dorsum of nude mice. Tumor growth was assessed on a 
daily basis. When tumors reached a size of 3–4 mm in diameter (between 2 and 3 weeks), a custom built dorsal 
skinfold chamber was implanted on the back of the mouse, as previously described29. Briefly, mice were anes-
thetized and kept warm using a heating pad throughout the surgical procedure. A skinfold was created on the 
dorsum of the mouse to obtain the tumor on one side and clear skin on the other. The layer of skin on the back 
of the tumor was removed surgically in order to fit the glass coverslip. Once completed, this model allowed a 
visual access to the vascular network of tumor and surrounding tissue over multiple days with no further surgical 
re-intervention.
Fluorescence Intravital Microscopy. Dorsal skinfold chambers were imaged using a fluorescent upright 
microscope Carl Zeiss Axiotech Vario 100 microscope equipped with a Hg-arc lamp (OSRAM GmbH, Augsburg, 
Germany) filtered for excitation at 470 ± 20 nm (Carl Zeiss “cube filter set 09”, exc BO 450–490, DM FT510, em 
LP515) and powered through a variable Carl Zeiss FluoArc device that allowed to dim the light power in order 
to prevent excessive excitation and photobleaching during imaging. Achroplan Carl Zeiss 2.5 x /0.0075 and a 
4 x /0.10 Plan Neofluar objectives were used for a large field view (3 × 3 mm2 for the 4 x objective) and a 20 x /0.50 
water immersion objective was used for close observation of the capillaries (field of view 600 × 600 µm2). The 
mouse was placed in a lateral decubitus position inside a plexiglas tube that was positioned under the microscope. 
The chamber was fixed horizontally which allowed performing transillumination and epi-illumination with no 
change in animal position (Fig. S3). Real-time images were recorded by a CCD camera (EM-CCD C9100-12, 
400–1000 nm, Hamamatsu Photonics, Solothurn, Switzerland) using an exposure time of 500 ms and a gain fac-
tor of 10. The Hamamatsu HiPic version 7.0 software produced 16-bit grey level images with a size of 512 × 512 
pixels. Prior to imaging, a fluorescent dye was injected intravenously (100 µL of sterile-filtered FITC-dextran 
2,000 kDa (10 mgmL−1) in 0.9% NaCl solution into the lateral tail vein. Real-time imaging was started after a cir-
culation time of 5 min and followed over a period of 30 min with an image acquisition every 10 min. Each mouse 
was imaged every other day for up to 21 days post surgery.
Image Analysis. Image analysis was performed using the ImageJ/Fiji 1.5.1 software (Wayne Rasband, NIH, 
USA). Total vessel density in dorsal skinfold chambers was assessed using the DeBacker method30. Briefly, a min-
imum of three 91 × 91 pixels regions of interest (ROI) excluding necrotic areas was randomly selected on each 
image (N = 4 for controls and N = 3 for RAPTA-T treated). On each ROI, three equidistant horizontal and three 
equidistant vertical lines were drawn. The number of vessels crossing the lines was counted manually and vessel 
density was reported as the DeBacker score index (number of vessels crossing the lines divided by the total length 
[mm] of the lines). These results were then validated on tumor sections stained for CD31 by quantifying the area 
of CD31 positive vessels. In addition, mean vessel diameters on these sections were quantified by measuring man-
ually the largest distance within cross-sectioned vessels. For each tumor 10 different fields (approx. 300 × 300 µm) 
were randomly chosen for analysis. Fractions of hypoxic tissue were assessed with the IHC tool of ImageJ/Fiji and 
were defined as the area fraction of the tissue showing positive pimonidazole staining.
Heterotopic Tumor Model and Treatment Protocol. Tumors were grown by subcutaneous injec-
tion of 1 × 106 MSTO-211H mesothelioma cells in 100 µL of serum-free RPMI 1640 medium on the flank of 
seven-week-old mice. Treatment was started after 4–5 weeks when tumors reached a volume of 100 mm3. Animals 
were randomly divided into four groups (N = 5 per group). (I) Control Group: one intraperitoneal (i.p.) injection 
of 100 µL of 0.9% NaCl (aq.) per day for 10 consecutive days. (II) RAPTA-T Group: 50 mg kg−1 of RAPTA-T in 
0.9% NaCl (aq.) (total volume 100 µL) i.p. per day for 10 consecutive days. (III) Combined RAPTA-T/cisplatin 
group: 50 mg kg−1 of RAPTA-T i.p. per day for 10 consecutive days followed by i.p. administration of 4 mg kg−1 
of cisplatin in 0.9% NaCl (aq.) on day 11. (IV) Cisplatin control group: 100 µL of l 0.9% NaCl (aq.) i.p. each day 
for 10 consecutive days followed by 4 mg kg−1 i.p. injection of cisplatin in 0.9% NaCl (aq.) on day 11. The tumor 
volume was measured with a digital caliper every 2 days and calculated using the modified ellipsoid formula V = 
(L × l2)/2, where L is the widest and l the smallest diameter.
Immunohistochemistry and Immunofluorescence. To obtain tissue sections for pericyte coverage 
assessment, tissues were fixed by transcardial perfusion of 10% neutral buffered formalin solution at a controlled 
pressure of 70 mmHg applied right after animal death induced by pentobarbital injection. Tumors were harvested, 
fixed in 10% neutral buffered formalin solution for 24 h, immersed in 30% sucrose solution for 48 h, washed in 
PBS and embedded in paraffin or frozen in cryo-embedding medium (OCT Bioptica, Milan Italy). For CD31 
staining, 8 µm thick paraffin sections were used. Tumor sections were deparaffinized, rehydrated and antigen 
retrieval was performed in 10 mM citrate buffer (pH 6.0) for 20 min at 95 °C. Endogenous peroxidase activity was 
inhibited by incubation with 3% H2O2 for 10 min in the dark. After blocking nonspecific reactivity with 1% BSA 
for 30 min, samples were incubated overnight 4 °C with rat anti-CD31 antibody (1:100, DIA-310-M, Dianova, 
Hamburg, Germany), followed by ImmPRESS HRP anti-rat IgG secondary antibody (Vector Laboratories, 
Burlingame, USA) for 30 min at room temperature. The immunoreaction was developed using diaminobenzi-
dine peroxide solution. Cell nuclei were counterstained with hematoxylin. Double-immunofluorescence staining 
of CD31 and α-SMA was performed on 8 µm thick frozen sections. Endothelial cells were stained by anti-CD31 
as described above. Pericytes were stained by anti-α-SMA (1:100, 1A4, Dako, Glostrup, Denmark) antibody 
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for 40 min at room temperature, followed by secondary antibodies donkey anti-mouse Alexa488 (1:800) and 
goat anti-rat Alexa568 (1:1000). To detect tumor hypoxia, 60 mg kg−1 pimonidazole was injected intravenously 
1 h before animals were sacrificed. Tumors were rapidly resected and frozen at −80 °C. A Hypoxyprobe-Kit 
(Chemicon, Burlington, MA, USA) was used to detect pimonidazole-protein adducts following the manufactur-
er’s protocol. All quantitative studies were carried out on preparations cut sagittally through the central regions 
of tumors.
Pericyte Coverage Assessment. All sections were scanned by an epifluorescent Olympus microscope 
equipped with an Olympus XM10 B/W camera and an Olympus Slide Scanner VS120-L100 (all performed with a 
20x objective). To estimate pericyte coverage, the overlap between α-SMA+ signal and CD31+ signal in MSTO-
211H tumors (3 mice per group with 15 different 300 × 300 µm size fields per section). The BIOP Threshold 
Finder plugin of ImageJ/Fiji was used to determine the best threshold levels for the CD31 and α-SMA signals, 
which were then applied to all images. The Colocalization plugin function of ImageJ/Fiji was used to identify the 
number of overlapping pixels from the thresholded images. The amount of colocalization was expressed as the 
overlapping pixels divided by the total CD31+ pixels from the thresholded images. Cancer-associated fibroblasts 
were considered present if α-SMA immunoreactivity was visible anywhere away from the vessel perimeter. To 
estimate the number of cancer-associated fibroblasts, α-SMA-positive cells which are not associated to endothe-
lial cells were counted on the same tumor sections using ImageJ/Fiji.
Quantification of Cisplatin and Ruthenium Drug Uptake in Tumors. Ruthenium and platinum con-
tent in explanted MSTO-211H tumors from different treatment groups was assessed by Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS). The tumor samples were digested with 400 µL of 69% HNO3 for 24 h at 
room temperature and adjusted with ultrapure water to a final volume of 4 mL. Indium was added as an internal 
standard at a concentration of 1ppb. External standards were prepared gravimetrically in an identical matrix to 
the samples (with regard to internal standard and nitric acid) with single element standards. Ru, Pt and In stand-
ard solutions (1gL−1 in 2% HNO3, 2% HNO3 and 10% HCl, respectively) were purchased from CPI International 
(Amsterdam, The Netherlands). Determinations of total metal contents were achieved on an Elan DRC II ICP-MS 
instrument (Perkin Elmer, Switzerland) equipped with a Meinhard nebulizer and a cyclonic spray chamber.
Interstitial Fluid Pressure Determination. IFP was measured in the center of tumors using the 
wick-in-needle-technique12,31. A custom-made 25-gauge needle with a 1 mm side hole located approximately 
2 mm from the needle tip was coupled to a pressure sensor by a water column in polyethylene tubing (0.54 mm 
inner diameter), filled with heparinized water (70 UmL−1). Two nylon sutures (6-0) were threaded through the 
needle to form the “wick.” The signal from the pressure sensor was passed through an amplifier and digitalized 
in a MacLab/4e AD Instrument Corporation (Dunedin, New Zealand) converter. Data were collected using the 
PowerLab Chart software version 4.2 (AD Instruments Ltd). Care was taken to exclude air bubbles from the entire 
system. Before each experiment, the system was calibrated against a defined height by placing the needle at the 
level of insertion (zero reference) and at a defined elevation of 30 cm. Following anesthesia, one needle was then 
introduced at the center of the tumor and another calibrated needle was placed parallel under the normal skin 
5 mm apart and at the same height of the tumor. Fluid communication between the tumor or subcutaneous tissue 
and the pressure transducer was checked by briefly clamping the tubing, hence causing a brief compression and 
decompression of the tube; when fluid communication was satisfactory, IFP quickly returned to the same value 
as before the clamping operation. Changes of interstitial fluid pressure were determined at three timepoints (day 
0, 4 and 8) following control or RAPTA treatment over a total time course of 8 days. Three independent measure-
ments were taken where IFP values for each measurement were followed over a period of at least 15 min with brief 
clamping every 5 min. The values after clamping were allowed to stabilize and give the mean IFP per measure-
ment. After each measurement, the needle was removed and calibration was checked against the 0 and the 30 cm 
value to ensure no clogging had occurred and that fluid communication was free. For each tumor the change in 
IFP over time is reported by subtracting the initial tumor IFP at day 0 from the IFP of each time point (day 0, 4 
and 8). One animal in the control group (N = 7) showed a continuous decrease in IFP over 8 days and two animals 
in the treatment group (N = 9) had an increase in IFP over 8 days and were excluded as outliers from the analysis.
Orthotopic Tumor Xenograft Model and Treatment Protocol. Mice were anaesthetized with keta-
mine/xylazine and placed in position of the right lateral decubitus. A 29 gauge needle of a 500 μL syringe was 
advanced through the fourth intercostal space for about 5 mm, into the left pleural cavity, and 106 H-MESO-
1-lucP cells suspended in 100 μL of PBS were injected. Treatment was started 3weeks thereafter, when tumors 
reached a volume with a photon flux >2 × 105. Animals were randomly divided into two groups (N = 4 per 
group), and treatment was given in a total volume of 100 μL consisting of (I) Group control: one i.p. injection 
of 0.9% NaCl (aq.) for 8 consecutive days every 24 h, (II) Group RAPTA-T: one i.p. injection of RAPTA-T 
(50 mg kg−1) in 0.9% NaCl (aq.) for 8 consecutive days every 24 h. A single injection of lipoplatin (18 mg kg−1; 
corresponds to one third of the LD50 in mice) was administered i.p. on day 9 to both groups.
Bioluminescence Imaging. Tumor sizes were assessed by bioluminescence measurement using the IVIS 
Imaging System (Caliper Life Sciences, Hanover, MD) as previously described. Briefly, 100 μL of D-luciferin (30 
mgmL−1, Promega, Dübendorf, Switzerland) were injected i.p. 15 min prior imaging. During the entire course 
of monitoring, the animals were stilled by isoflurane anesthesia. The tumor sites showing bioluminescence were 
identified as the regions of interest (ROI) and the total photon counts were quantified using the software Living 
Image 3.1.0 (Caliper Life Sciences). The tumor volume (or ROI) was measured by bioluminescence imaging 
two times per week over a period of 29 days and was determined by subtracting the bioluminescence signal of a 
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control mouse with no implanted tumor. The tumor volume in each group was expressed as the average values of 
the total photon counts.
Statistical Analysis. Values are given as mean values ± standard deviation (SD) if not otherwise stated. 
Statistical analysis was performed with GraphPad Prism software (GraphPad Software Inc., CA). Statistical tests, 
group sizes and P values are given in the corresponding figure legends. P values < 0.05 were considered statisti-
cally significant.
Data Availability. The datasets generated during and analyzed during the current study are available from 
the corresponding author.
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